— Viking Therapeutics Inc. (NASDAQ: VKTX) reported Q3 2019 loss of $0.08 per share, vs. a loss of $0.13 expected.
— Net loss amounted to $5.7 million compared to $6.6 million last year.
— R&D expenses were $5.3 million compared to $5.7 million in the year-ago quarter.
— General and administrative expenses were $2.2 million compared to $1.7 million last year.
— At quarter-end, the company had cash, cash equivalents and short-term investments of $288.1 million.
— VKTX shares gained 0.15% following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
AAPL Earnings: Apple’s Q2 sales and profit beat estimates; iPhone sales down 10%
Apple Inc. (NASDAQ: AAPL) on Thursday reported better-than-expected profit and revenue for the second quarter of 2024. There was a 10% decrease in iPhone sales. The gadget giant reported revenues
Shopify (SHOP) is all set to report Q1 2024 results. Here’s what to expect
Over the years, Shopify Inc. (NYSE: SHOP) has steadily expanded its footprint in the online retail market through constant innovation, like the recent launch of a mobile POS device for
eBay (EBAY): A look at how the ecommerce company fared in Q1 2024
Shares of eBay Inc. (NASDAQ: EBAY) were down over 2% on Thursday. The company reported its earnings results for the first quarter of 2024 a day ago, with revenue and
